Overview

All Sanguine study protocols and their resulting samples, which include all Sanguine at-home and apheresis collection programs, are conducted under an Institutional Review Board (IRB). Sanguine operates under an electronic informed consent process which executes 21 CFR part 11 compliant e-signatures, and Sanguine systems interacting with study participant information are HIPAA-compliant.

Sanguine’s CD56+ NK cells from healthy donors provide researchers with a robust source of innate immune cells for oncology, infectious disease, and immunotherapy research. These highly cytotoxic cells, collected from healthy donors, support studies on immune surveillance, tumor cell targeting, and the development of NK cell-based therapies. CD56+ NK cells are collected by negative selection from fresh cells by labeling with antibody complexes and magnetically separated. CD56+ cells are aliquoted and stored using CryoStor® CS10 freezing media.